Best Healthcare Cost Articles of 2021
ICER's assessment of Biogen's controversial Alzheimer's drug, Aduhelm, was among the most read MHE articles about healthcare costs in 2021.
Ready or Not, the New Year Brings Trump’s Price Transparency Rule
The U.S. Circuit Court of Appeals of the District of Columbia ruled that the rule could take effect.
Pharma Makers Hike Drug Prices 3.1% in July
The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.
ICER Says Alzheimer's Drug Aducanumab Should Be Priced at Between $2,560-$8,290
The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.
Rituximab Biosimilars Produce Big Cost Savings, Are Effective
A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
ICER Foresees AstraZeneca’s Tezepelumab for Severe Asthma As Being Only Modestly Cost Effective
Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveat the anticipated price, according to the cost-effectiveness group's calculations.
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
